Cargando…

Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases

Resistin-like molecules (RELMs) are highly cysteine-rich proteins, including RELMα, RELMβ, Resistin, and RELMγ. However, RELMs exhibit significant differences in structure, distribution, and function. The expression of RELMs is regulated by various signaling molecules, such as IL-4, IL-13, and their...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yaning, Zhu, Neng, Qiu, Yun, Tan, Junlan, Wang, Feiying, Qin, Li, Dai, Aiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869618/
https://www.ncbi.nlm.nih.gov/pubmed/36691020
http://dx.doi.org/10.1186/s12964-022-01032-w
_version_ 1784876806457786368
author Shi, Yaning
Zhu, Neng
Qiu, Yun
Tan, Junlan
Wang, Feiying
Qin, Li
Dai, Aiguo
author_facet Shi, Yaning
Zhu, Neng
Qiu, Yun
Tan, Junlan
Wang, Feiying
Qin, Li
Dai, Aiguo
author_sort Shi, Yaning
collection PubMed
description Resistin-like molecules (RELMs) are highly cysteine-rich proteins, including RELMα, RELMβ, Resistin, and RELMγ. However, RELMs exhibit significant differences in structure, distribution, and function. The expression of RELMs is regulated by various signaling molecules, such as IL-4, IL-13, and their receptors. In addition, RELMs can mediate numerous signaling pathways, including HMGB1/RAGE, IL-4/IL-4Rα, PI3K/Akt/mTOR signaling pathways, and so on. RELMs proteins are involved in wide range of physiological and pathological processes, including inflammatory response, cell proliferation, glucose metabolism, barrier defense, etc., and participate in the progression of numerous diseases such as lung diseases, intestinal diseases, cardiovascular diseases, and cancers. Meanwhile, RELMs can serve as biomarkers, risk predictors, and therapeutic targets for these diseases. An in-depth understanding of the role of RELMs may provide novel targets or strategies for the treatment and prevention of related diseases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-01032-w.
format Online
Article
Text
id pubmed-9869618
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98696182023-01-24 Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases Shi, Yaning Zhu, Neng Qiu, Yun Tan, Junlan Wang, Feiying Qin, Li Dai, Aiguo Cell Commun Signal Review Resistin-like molecules (RELMs) are highly cysteine-rich proteins, including RELMα, RELMβ, Resistin, and RELMγ. However, RELMs exhibit significant differences in structure, distribution, and function. The expression of RELMs is regulated by various signaling molecules, such as IL-4, IL-13, and their receptors. In addition, RELMs can mediate numerous signaling pathways, including HMGB1/RAGE, IL-4/IL-4Rα, PI3K/Akt/mTOR signaling pathways, and so on. RELMs proteins are involved in wide range of physiological and pathological processes, including inflammatory response, cell proliferation, glucose metabolism, barrier defense, etc., and participate in the progression of numerous diseases such as lung diseases, intestinal diseases, cardiovascular diseases, and cancers. Meanwhile, RELMs can serve as biomarkers, risk predictors, and therapeutic targets for these diseases. An in-depth understanding of the role of RELMs may provide novel targets or strategies for the treatment and prevention of related diseases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-01032-w. BioMed Central 2023-01-23 /pmc/articles/PMC9869618/ /pubmed/36691020 http://dx.doi.org/10.1186/s12964-022-01032-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Shi, Yaning
Zhu, Neng
Qiu, Yun
Tan, Junlan
Wang, Feiying
Qin, Li
Dai, Aiguo
Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases
title Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases
title_full Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases
title_fullStr Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases
title_full_unstemmed Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases
title_short Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases
title_sort resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869618/
https://www.ncbi.nlm.nih.gov/pubmed/36691020
http://dx.doi.org/10.1186/s12964-022-01032-w
work_keys_str_mv AT shiyaning resistinlikemoleculesamarkermediatorandtherapeutictargetformultiplediseases
AT zhuneng resistinlikemoleculesamarkermediatorandtherapeutictargetformultiplediseases
AT qiuyun resistinlikemoleculesamarkermediatorandtherapeutictargetformultiplediseases
AT tanjunlan resistinlikemoleculesamarkermediatorandtherapeutictargetformultiplediseases
AT wangfeiying resistinlikemoleculesamarkermediatorandtherapeutictargetformultiplediseases
AT qinli resistinlikemoleculesamarkermediatorandtherapeutictargetformultiplediseases
AT daiaiguo resistinlikemoleculesamarkermediatorandtherapeutictargetformultiplediseases